The primary goals during anesthesia in end-stage renal disease patients are to maintain hemodynamic stability, avoid fluid overload, and carefully manage drug administration.
Monitoring: Standard anesthetic monitoring, including ECG, pulse oximetry, capnography, and non-invasive blood pressure monitoring, should be employed. Invasive monitoring such as arterial lines or central venous pressure (CVP) monitoring may be considered for major surgeries or in patients with unstable cardiovascular status. Care should be taken to avoid the use of arteriovenous fistulae for blood pressure monitoring or venous access.
Fluid Management: ESRD patients are often volume-sensitive, and their ability to handle fluid shifts is severely impaired. Fluid management should be conservative, guided by clinical parameters such as CVP or invasive hemodynamic monitoring. Crystalloid solutions should be used cautiously, and hypotonic fluids should be avoided to prevent hyponatremia. If volume replacement is needed, balanced solutions are preferred, and colloids may be used in cases of significant fluid loss.
Anesthetic Agents: Anesthetic drug selection should take into account the altered pharmacokinetics in ESRD. Intravenous induction agents such as propofol and etomidate are generally safe, as they undergo hepatic metabolism and have minimal renal clearance. However, thiopental and benzodiazepines should be used cautiously due to their increased unbound fraction in the setting of hypoalbuminemia. Opioids such as fentanyl and sufentanil are preferred over morphine and meperidine, as the latter accumulate active metabolites that can lead to prolonged sedation and neurotoxicity.
Muscle Relaxants: The choice of neuromuscular blocking agents is important in ESRD. Succinylcholine should generally be avoided due to the risk of hyperkalemia, especially in patients with baseline elevated potassium levels. Atracurium and cisatracurium, which undergo Hofmann elimination, are the agents of choice as they are independent of renal function. Vecuronium and rocuronium may be used, but their elimination is slower in ESRD, so repeated dosing or prolonged infusions should be avoided.
Inhalational Agents: Sevoflurane, isoflurane, and desflurane can be used safely in ESRD patients. Although there has been concern about the potential nephrotoxicity of sevoflurane due to the production of compound A, studies have shown that it is safe in patients with renal impairment. The choice of volatile agent should be based on the patient's hemodynamic status and other clinical considerations.
